• Innate Pharma launched a private placement of ordinary shares targeting about EUR 22.5 million, marketed to qualified and institutional investors.
• Offering includes a Rule 144A tranche in the US, with shares sold under an exemption from Securities Act registration.
• Proceeds earmarked mainly for IPH4502 clinical development, with funding also for preclinical ADC programs, working capital, corporate needs.
• Pricing set via accelerated bookbuild; issue price not below the 5-session VWAP on Euronext Paris, with a maximum 15% discount.
• Bpifrance committed to place a EUR 3 million order; company, directors, certain executives to observe 90-day lock-ups.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-057935), on August 19, 2026, and is solely responsible for the information contained therein.